Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients.

[1]  M. Hecker,et al.  High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients* , 2016, Molecular & Cellular Proteomics.

[2]  Rongxin Zhang,et al.  Epigenetics in autoimmune diseases: Pathogenesis and prospects for therapy. , 2015, Autoimmunity reviews.

[3]  F. Petersen,et al.  Revisiting the role of mast cells in autoimmunity. , 2015, Autoimmunity reviews.

[4]  L. Kappos,et al.  Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis , 2015, Neurology.

[5]  J. C. Love,et al.  Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis , 2015, Science Translational Medicine.

[6]  H. Hartung,et al.  Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab‐associated progressive multifocal leukoencephalopathy , 2014, Annals of neurology.

[7]  J. Fraussen,et al.  Targets of the humoral autoimmune response in multiple sclerosis. , 2014, Autoimmunity reviews.

[8]  À. Rovira,et al.  N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis , 2014, Journal of Neurology.

[9]  S. Sadiq,et al.  Biomarkers of Therapeutic Response in Multiple Sclerosis: Current Status , 2014, Molecular Diagnosis & Therapy.

[10]  M. Romero,et al.  Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study , 2014, The Lancet Neurology.

[11]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 2014, Neurology.

[12]  M. Ban,et al.  Multiple sclerosis genetics , 2014, The Lancet Neurology.

[13]  R. Reynolds,et al.  Differential loss of KIR4.1 immunoreactivity in multiple sclerosis lesions , 2014, Annals of neurology.

[14]  S. Kuerten,et al.  KIR4.1 Antibodies as Biomarkers in Multiple Sclerosis , 2014, Front. Neurol..

[15]  C. Raoul,et al.  Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis , 2014, Multiple sclerosis.

[16]  K. Blennow,et al.  CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment , 2014, Journal of Neuroimmunology.

[17]  Ariel Miller,et al.  Revised diagnostic criteria of multiple sclerosis. , 2014, Autoimmunity reviews.

[18]  H. Wiendl,et al.  Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner , 2014, Therapeutic advances in neurological disorders.

[19]  Yuan Zhou,et al.  The potential role of epigenetic modifications in the heritability of multiple sclerosis , 2014, Multiple sclerosis.

[20]  H. Zetterberg,et al.  Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis , 2014, Multiple sclerosis.

[21]  M. Mehler,et al.  Developing epigenetic diagnostics and therapeutics for brain disorders. , 2013, Trends in molecular medicine.

[22]  L. Kappos,et al.  Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis , 2013, Acta neurologica Scandinavica.

[23]  Massimiliano Calabrese,et al.  Clinical, MRI, and CSF Markers of Disability Progression in Multiple Sclerosis , 2013, Disease markers.

[24]  H. Hartung,et al.  Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis , 2013, Neurology.

[25]  A. Bartoš,et al.  Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis , 2013, Journal of Neuroimmunology.

[26]  J. K. Ho,et al.  Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab , 2013, Journal of Neuroimmunology.

[27]  K. Rostásy,et al.  The spectrum of MOG autoantibody-associated demyelinating diseases , 2013, Nature Reviews Neurology.

[28]  A. Mandal,et al.  Diverse pathological implications of YKL-40: answers may lie in 'outside-in' signaling. , 2013, Cellular signalling.

[29]  F. Fazekas,et al.  Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis , 2013, Multiple sclerosis.

[30]  Y. Zhang,et al.  Soluble CD146 in cerebrospinal fluid of active multiple sclerosis , 2013, Neuroscience.

[31]  K. Clark,et al.  Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis , 2013, Multiple sclerosis.

[32]  G. Giovannoni,et al.  Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[33]  T. Olsson,et al.  Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients. , 2013, Journal of proteome research.

[34]  M. Anagnostouli,et al.  Biomarkers in Multiple Sclerosis: An Up-to-Date Overview , 2013, Multiple sclerosis international.

[35]  J. W. Lindsey,et al.  The antibody response to Epstein–Barr virions is altered in multiple sclerosis , 2013, Journal of Neuroimmunology.

[36]  B. Engelhardt,et al.  Capture, crawl, cross: the T cell code to breach the blood-brain barriers. , 2012, Trends in immunology.

[37]  R. Gold,et al.  Regulated microRNAs in the CSF of patients with multiple sclerosis , 2012, Neurology.

[38]  P. Sørensen,et al.  Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis , 2012, Journal of Neuroinflammation.

[39]  Bernhard Hemmer,et al.  Potassium channel KIR4.1 as an immune target in multiple sclerosis. , 2012, The New England journal of medicine.

[40]  M. Buttmann,et al.  Intrathecal, Polyspecific Antiviral Immune Response in Oligoclonal Band Negative Multiple Sclerosis , 2012, PloS one.

[41]  A. Odén,et al.  Serum and CSF measles antibody levels increase over time in patients with multiple sclerosis or clinically isolated syndrome , 2012, Journal of Neuroimmunology.

[42]  Michael Khalil,et al.  Neurofilaments as biomarkers in multiple sclerosis , 2012, Multiple sclerosis.

[43]  R. Feng,et al.  Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients , 2012, Journal of Neuroimmunology.

[44]  M. Kamasak,et al.  Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis , 2012, Multiple sclerosis.

[45]  Y. Long,et al.  Aquaporin 4 Antibodies in the Cerebrospinal Fluid Are Helpful in Diagnosing Chinese Patients with Neuromyelitis Optica , 2012, Neuroimmunomodulation.

[46]  Chih-Chien Wang,et al.  Current Status of the Immunomodulation and Immunomediated Therapeutic Strategies for Multiple Sclerosis , 2011, Clinical & developmental immunology.

[47]  U. Ziemann,et al.  Development of biomarkers for multiple sclerosis as a neurodegenerative disorder , 2011, Progress in Neurobiology.

[48]  J. Bennett,et al.  Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis , 2011, Journal of Neuroimmunology.

[49]  H. Hartung,et al.  Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis , 2011, Annals of neurology.

[50]  A. Vaheri,et al.  Intrathecal human herpesvirus 6 antibodies in multiple sclerosis and other demyelinating diseases presenting as oligoclonal bands in cerebrospinal fluid , 2011, Journal of Neuroimmunology.

[51]  T. Olsson,et al.  Epstein-Barr virus and multiple sclerosis: interaction with HLA , 2011, Genes and Immunity.

[52]  J. Fleming,et al.  Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies , 2011, Multiple sclerosis international.

[53]  M. Mori,et al.  Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica. , 2011, Archives of neurology.

[54]  J. Graber,et al.  Biomarkers of disease activity in multiple sclerosis , 2011, Journal of the Neurological Sciences.

[55]  J. Correale,et al.  Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis , 2011, Multiple sclerosis.

[56]  Xiaoli Yu,et al.  Viruses and multiple sclerosis. , 2011, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[57]  B. Sharrack,et al.  Central inflammation versus peripheral regulation in multiple sclerosis , 2011, Journal of Neurology.

[58]  T. Olsson,et al.  Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course , 2011, Multiple sclerosis.

[59]  K. Rostásy,et al.  Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. , 2011, Clinical immunology.

[60]  G. Giovannoni,et al.  After the storm , 2011, Neurology.

[61]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[62]  C. Wegner,et al.  Inflammation, demyelination, and degeneration - recent insights from MS pathology. , 2011, Biochimica et biophysica acta.

[63]  P. Sørensen,et al.  Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis , 2011, Multiple sclerosis.

[64]  H. Bartosik-Psujek,et al.  Impact of cladribine on soluble adhesion molecules in multiple sclerosis , 2010, Acta neurologica Scandinavica.

[65]  S. Sadiq,et al.  Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis , 2010, Neurobiology of Disease.

[66]  F. Paul,et al.  Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance , 2010, Journal of Neuroinflammation.

[67]  T. Luider,et al.  Proteomics Comparison of Cerebrospinal Fluid of Relapsing Remitting and Primary Progressive Multiple Sclerosis , 2010, PloS one.

[68]  Y. Itoyama,et al.  Astrocytic damage is far more severe than demyelination in NMO , 2010, Neurology.

[69]  A. Starkey,et al.  In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases , 2010, Journal of Neuroinflammation.

[70]  T. Olsson,et al.  Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. , 2010, Journal of proteomics.

[71]  Lawrence Steinman,et al.  T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis , 2010, Nature Medicine.

[72]  À. Rovira,et al.  Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. , 2010, Brain : a journal of neurology.

[73]  T. Olsson,et al.  Interleukin 18 Receptor 1 expression distinguishes patients with multiple sclerosis , 2010, Multiple Sclerosis.

[74]  Jan Hillert,et al.  Gene expression profiling in multiple sclerosis: A disease of the central nervous system, but with relapses triggered in the periphery? , 2010, Neurobiology of Disease.

[75]  J. Salzer,et al.  Neurofilament light as a prognostic marker in multiple sclerosis , 2010, Multiple sclerosis.

[76]  J. Fleming,et al.  A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking , 2009, Neurology.

[77]  E. Tolosa,et al.  Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. , 2009, Brain : a journal of neurology.

[78]  H. Hartung,et al.  Cerebrospinal fluid biomarkers in multiple sclerosis , 2009, Neurobiology of Disease.

[79]  F. Bouwman,et al.  Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis , 2009, Neurology.

[80]  M. Khademi,et al.  The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment‐sensitive biomarkers , 2009, European journal of neurology.

[81]  J. Brettschneider,et al.  CSF proteome analysis in clinically isolated syndrome (CIS): Candidate markers for conversion to definite multiple sclerosis , 2009, Neuroscience Letters.

[82]  F. Birklein,et al.  High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid , 2009, Acta neurologica Scandinavica.

[83]  T. Brücke,et al.  Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis , 2008, Journal of Neurology.

[84]  E. Merelli,et al.  A multifactorial prognostic index in multiple sclerosis , 2008, Journal of Neurology.

[85]  G. Niepel,et al.  Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. , 2008, Archives of neurology.

[86]  E. Radue,et al.  Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis , 2008, Annals of neurology.

[87]  R. Schneider,et al.  Intrathecal IgM‐synthesis does not correlate with the risk of relapse in patients with a primary demyelinating event , 2007, European journal of neurology.

[88]  J. Kukal,et al.  Antibodies against light neurofilaments in multiple sclerosis patients , 2007, Acta neurologica Scandinavica.

[89]  S. Süssmuth,et al.  Cerebrospinal fluid proteome profile in multiple sclerosis , 2007, Multiple sclerosis.

[90]  Ludwig Kappos,et al.  Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring , 2007, The Lancet Neurology.

[91]  J. Kukal,et al.  Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis , 2007, Journal of Neurology.

[92]  H. Hartung,et al.  Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis , 2006, Proceedings of the National Academy of Sciences.

[93]  E. Waubant.  Biomarkers Indicative of Blood-Brain Barrier Disruption in Multiple Sclerosis , 2006, Disease markers.

[94]  H. Link,et al.  Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness , 2006, Journal of Neuroimmunology.

[95]  K. Trinkaus,et al.  Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis , 2006, Neurology.

[96]  J. Lycke,et al.  IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: Implications for their possible immunopathogenic roles , 2006, Journal of Neuroimmunology.

[97]  M. Sá,et al.  Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis , 2006, Multiple sclerosis.

[98]  H. Tumani,et al.  Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis , 2006, Multiple sclerosis.

[99]  M. Calabrese,et al.  Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[100]  S. Yokota,et al.  Autoantibodies against HSP70 family proteins were detected in the cerebrospinal fluid from patients with multiple sclerosis , 2006, Journal of the Neurological Sciences.

[101]  D. Pham‐Dinh,et al.  Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[102]  M. Sospedra,et al.  Clonotypic analysis of cerebrospinal fluid T cells during disease exacerbation and remission in a patient with multiple sclerosis , 2006, Journal of Neuroimmunology.

[103]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[104]  K. Büssow,et al.  Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. , 2005, The Journal of clinical investigation.

[105]  P. Maly-Sundgren,et al.  Predicting the Outcome of Optic Neuritis , 2005, Journal of Neurology.

[106]  T. Derfuss,et al.  Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B–cell response , 2005, Journal of Neurology.

[107]  E. İdiman,et al.  Intrathecal sICAM-1 production in multiple sclerosis Correlation with triple dose Gd-DTPA MRI enhancement and IgG index , 2005, Journal of Neurology.

[108]  E. Sueoka,et al.  Autoantibodies against heterogeneous nuclear ribonucleoprotein B1 in CSF of MS patients , 2004, Annals of neurology.

[109]  À. Rovira,et al.  CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS , 2004, Journal of Neurology.

[110]  Roland Martin,et al.  Development of biomarkers in multiple sclerosis. , 2004, Brain : a journal of neurology.

[111]  J. Archelos,et al.  Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG , 2004, Journal of Neurology.

[112]  M. Schluep,et al.  Detection of oligoclonal free kappa chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[113]  T. Olsson,et al.  Antibody Cross-Reactivity between Myelin Oligodendrocyte Glycoprotein and the Milk Protein Butyrophilin in Multiple Sclerosis 1 2 , 2004, The Journal of Immunology.

[114]  K. Nékám,et al.  Investigation of cytokine (tumor necrosis factor‐alpha, interleukin‐6, interleukin‐10) concentrations in the cerebrospinal fluid of female patients with multiple sclerosis and systemic lupus erythematosus , 2004, European journal of neurology.

[115]  J. Correale,et al.  Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS , 2003, Journal of Neuroimmunology.

[116]  Jeffrey A. Cohen,et al.  Intracranial arterial dolichoectasia and its relation with atherosclerosis and stroke subtype , 2003, Neurology.

[117]  S. Cook,et al.  Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis , 2003, Journal of Neuroimmunology.

[118]  Y. Itoyama,et al.  Complementarity-Determining Region 3 Spectratyping Analysis of the TCR Repertoire in Multiple Sclerosis1 , 2003, The Journal of Immunology.

[119]  J. Masjuán,et al.  Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis , 2003, Annals of neurology.

[120]  F. Barkhof,et al.  Multiple sclerosis , 2003, Neurology.

[121]  V. Gallai†,et al.  Brain-derived neurotrophic factor in patients with multiple sclerosis , 2002, Journal of Neuroimmunology.

[122]  J. Masjuán,et al.  Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS , 2002, Neurology.

[123]  E. Silber,et al.  Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit , 2002, Neurology.

[124]  J. Masjuán,et al.  Intrathecal IgM synthesis in neurologic diseases: Relationship with disability in MS , 2002, Neurology.

[125]  R. Sánchez-Valle,et al.  14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis , 2001, Neurology.

[126]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[127]  Hansotto Reiber,et al.  Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs , 2001, Journal of the Neurological Sciences.

[128]  G. Levi,et al.  Isoprostanes, Novel Markers of Oxidative Injury, Help Understanding the Pathogenesis of Neurodegenerative Diseases , 2000, Neurochemical Research.

[129]  C. V. Jensen,et al.  Intrathecal IgG synthesis and autoantibody-secreting cells in multiple sclerosis , 2000, Journal of Neuroimmunology.

[130]  P. Kivisäkk,et al.  Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis , 1999, Multiple sclerosis.

[131]  M. Christiansen,et al.  Cerebrospinal fluid measures of disease activity in patients with multiple sclerosis , 1998, Multiple sclerosis.

[132]  A. Massaro.  Are there indicators of remyelination in blood or CSF of multiple sclerosis patients? , 1998, Multiple sclerosis.

[133]  J. Baudewig,et al.  Soluble adhesion molecules (sVCAM‐1 and sICAM‐1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis , 1997, Annals of neurology.

[134]  M. Sharief,et al.  Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis , 1991 .

[135]  N. Kasai,et al.  Anti-glycolipid antibodies and their immune complexes in multiple sclerosis , 1986, Journal of the Neurological Sciences.

[136]  J. Kurtzke.  DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF MULTIPLE SCLEROSIS , 1970, Acta neurologica Scandinavica.

[137]  H. Hartung,et al.  The CSF JCV antibody index for diagnosis of natalizumab-associated PML , 2014 .

[138]  S. Sadiq,et al.  Disease Biomarkers in Multiple Sclerosis , 2012, Molecular Diagnosis & Therapy.

[139]  A. Vaheri,et al.  Evidence for human herpesvirus 6 variant A antibodies in multiple sclerosis: diagnostic and therapeutic implications , 2011, Journal of NeuroVirology.

[140]  S. Izumo,et al.  Significantly increased antibody response to heterogeneous nuclear ribonucleoproteins in cerebrospinal fluid of multiple sclerosis patients but not in patients with human T-lymphotropic virus type I—associated myelopathy/tropical spastic paraparesis , 2011, Journal of NeuroVirology.

[141]  L. Rosengren,et al.  Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis , 2010, Journal of Neurology.

[142]  Jia Newcombe,et al.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. , 2008, The American journal of pathology.

[143]  J. Newcombe,et al.  Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. , 2006, Brain : a journal of neurology.

[144]  T. Olsson.  Multiple sclerosis:cerebrospinal fluid. , 1994 .